12,289 Shares in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Acquired by SG Americas Securities LLC

SG Americas Securities LLC bought a new position in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 12,289 shares of the biopharmaceutical company’s stock, valued at approximately $134,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Eventide Asset Management LLC increased its position in Marinus Pharmaceuticals by 42.8% in the third quarter. Eventide Asset Management LLC now owns 4,529,997 shares of the biopharmaceutical company’s stock worth $36,466,000 after purchasing an additional 1,356,800 shares during the period. Lion Point Capital LP grew its position in shares of Marinus Pharmaceuticals by 14.6% during the 4th quarter. Lion Point Capital LP now owns 4,222,648 shares of the biopharmaceutical company’s stock worth $21,480,000 after buying an additional 538,026 shares during the period. BlackRock Inc. raised its stake in shares of Marinus Pharmaceuticals by 245.4% during the second quarter. BlackRock Inc. now owns 3,897,770 shares of the biopharmaceutical company’s stock worth $42,330,000 after buying an additional 2,769,357 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Marinus Pharmaceuticals in the fourth quarter valued at approximately $13,990,000. Finally, Jennison Associates LLC boosted its stake in Marinus Pharmaceuticals by 58.4% in the third quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock valued at $23,791,000 after acquiring an additional 1,089,913 shares during the last quarter. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Trading Up 20.0 %

NASDAQ MRNS opened at $1.44 on Thursday. The stock has a market capitalization of $79.10 million, a price-to-earnings ratio of -0.55 and a beta of 0.91. Marinus Pharmaceuticals, Inc. has a 52 week low of $1.11 and a 52 week high of $11.26. The stock’s 50 day moving average price is $8.72 and its two-hundred day moving average price is $8.45. The company has a debt-to-equity ratio of 5.68, a quick ratio of 4.01 and a current ratio of 4.07.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The business had revenue of $7.19 million during the quarter, compared to the consensus estimate of $7.78 million. During the same period in the prior year, the firm earned ($0.76) EPS. As a group, analysts anticipate that Marinus Pharmaceuticals, Inc. will post -2.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MRNS has been the topic of a number of analyst reports. StockNews.com downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Robert W. Baird restated a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday. Royal Bank of Canada reissued a “sector perform” rating and set a $3.00 price target (down from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday. Finally, Oppenheimer reaffirmed a “market perform” rating and issued a $9.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $18.21.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.